The correlation with PD-1 and the presence of high PD-L1 and CD8+ in a small percentage of tumors suggest that PD-1 blockade might be a therapeutic option for a subset of embryonal rhabdomyosarcoma patients. Here, CD8A is linked to embryonal rhabdomyosarcoma.